TP53 and familial pancreatic carcinoma: A considerable number of the gene mutations reported in pancreatic cancer are attributed to KRAS, tumour protein p53 (TP53), SMAD4, and cyclin-dependent kinase inhibitor 2A (CDKN2A), and KRAS mutations account for approximately 90% of the pancreatic cancers [17,18].